BlackRock Fund Advisors’s Pernix Therapeutics Holdings, Inc. PTX Stock Holding History

BlackRock Fund Advisors’s Portfolio PTX Stock Details PTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$34K	Buy	17,315 +3,801	+28%	+$13.8K	﹤0.01%	3828
2016 Q3	$84K	Buy	13,514 +12,765	+1,704%	+$78.7K	﹤0.01%	3652
2016 Q2	$3K	Sell	749 -111,033	-99%	-$725K	﹤0.01%	4202
2016 Q1	$1.17M	Sell	111,782 -6,378	-5%	-$127K	﹤0.01%	3176
2015 Q4	$3.49M	Sell	118,160 -83,336	-41%	-$2.52M	﹤0.01%	3002
2015 Q3	$6.37M	Buy	201,496 +33,194	+20%	+$1.59M	﹤0.01%	2654
2015 Q2	$9.96M	Buy	168,302 +27,288	+19%	+$1.92M	﹤0.01%	2501
2015 Q1	$15.1M	Buy	141,014 +2,879	+2%	+$274K	﹤0.01%	2216
2014 Q4	$13M	Buy	138,135 +58,748	+74%	+$5.6M	﹤0.01%	2303
2014 Q3	$6.1M	Sell	79,387 -2,514	-3%	-$198K	﹤0.01%	2630
2014 Q2	$7.36M	Buy	81,901 +33,629	+70%	+$2.06M	﹤0.01%	2607
2014 Q1	$2.58M	Buy	48,272 +429	+0.9%	+$14.2K	﹤0.01%	3108
2013 Q4	$1.21M	Sell	47,843 -1,948	-4%	-$46.4K	﹤0.01%	3181
2013 Q3	$1.35M	Buy	49,791 +5,312	+12%	+$171K	﹤0.01%	3158
2013 Q2	$1.61M	Buy	+44,479	New	+$1.67M	﹤0.01%	3126

Other funds holding PTX

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Globeflex Capital San Diego, California $661M AUM 50.59% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock Fund Advisors's PTX Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Pernix Therapeutics Holdings, Inc. (PTX) stake by 28% in Q4 2016, buying an estimated $13.8K and bringing the position to 17,315 shares worth $34K. The position accounts for ﹤0.01% of the portfolio, ranked #3828.

BlackRock Fund Advisors first reported a position in PTX in Q2 2013 and has held it in 15 quarters since. The position peaked at $15.1M in Q1 2015. 34 funds tracked by Wall St. Rank hold PTX as of Q4 2016.

BlackRock Fund Advisors held 17,315 shares of Pernix Therapeutics Holdings, Inc. worth $34K as of Q4 2016.
BlackRock Fund Advisors bought 3,801 Pernix Therapeutics Holdings, Inc. shares in Q4 2016, an estimated $13.8K.
Pernix Therapeutics Holdings, Inc. made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #3828 holding.
BlackRock Fund Advisors first reported a position in Pernix Therapeutics Holdings, Inc. in Q2 2013 and has held it in 15 quarters since.
BlackRock Fund Advisors's Pernix Therapeutics Holdings, Inc. position peaked at $15.1M in Q1 2015.
34 funds tracked by Wall St. Rank held Pernix Therapeutics Holdings, Inc. as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.